Myhre syndrome

Last updated
Myhre syndrome
Other namesLAPS syndrome, Laryngotracheal stenosis, Arthropathy, Prognathism, and Short stature syndrome [1]
Autosomal dominant - en.svg
Myhre syndrome is inherited in an autosomal dominant manner [2]
Specialty Medical genetics

Myhre syndrome (MS) is an ultrarare genetic disorder caused by dominant gain-of-function (GOF) mutations in the SMAD4 gene. [3] MS mutations are missense heterozygous mutations affecting only Ile500 or Arg496 residues of the SMAD4 protein. [4] MS patients exhibit manifestations of connective tissue disease including dysfunction of the integumentary, cardiovascular, respiratory, gastrointestinal, and musculoskeletal systems and is often characterized by proliferative systemic fibrosis. [5] Some of these features are life threatening, such as airway or arterial narrowing (laryngotracheal stenosis or aortic coarctation) and fibroproliferation of tissues including lung, heart, and liver. [6] Consistent with these clinical observations, cells isolated from patients with MS demonstrate increased TGF-β signaling. [7]

Contents

In contrast, loss-of-function (LOF) mutations in SMAD4 predispose individuals to gastrointestinal polyps, a higher risk of colorectal cancer, and a risk of forming arteriovenous malformations (AVM) a hallmark manifestation of hereditary hemorrhagic telangiectasia (HHT). [8] Patients also have external phenotypes similar to Marfan syndrome. [9]

Biologically, SMAD4 plays a prominent role in both canonical TGF-β and other TGF-β superfamily signaling. [10] The systemic manifestations of these two disorders suggest opposite biologic effects, such as the finding of aortic aneurysm in SMAD4-JP-HHT (LOF of SMAD4) versus the aortic hypoplasia seen in Myhre syndrome (GOF in SMAD4). [9]

Signs and symptoms

The clinical presentation is variable but includes: [11] [12] [13] [14] [15] [16]

The facial abnormalities include:

The Musculo-skeletal abnormalities include:

Cardiovascular abnormalities include:

Other anomalies

Genetics

Myhre syndrome is due to mutations in the SMAD4 gene. [3] This gene encodes a protein - transducer mediating transforming growth factor beta. Some researchers believe that the SMAD4 gene mutations that cause Myhre syndrome impair the ability of the SMAD4 protein to attach (bind) properly with the other proteins involved in the signaling pathway. Other studies have suggested that these mutations result in an abnormally stable SMAD4 protein that remains active in the cell longer. Changes in SMAD4 binding or availability may result in abnormal signaling in many cell types, which affects development of several body systems and leads to the signs and symptoms of Myhre syndrome. [17] [18]

The patients of this disease exhibit hypertrophic phenotype in their muscle tissues. Myostatin target genes are found to be downregulated while bone morphogenetic protein (BMP) target genes display both upregulated and downregulated genotypes. [18]

Diagnosis

The diagnosis of Myhre syndrome is established in a proband with characteristic clinical findings and a heterozygous pathogenic (or likely pathogenic) variant in SMAD4 detected by molecular genetic testing. [11] Because Myhre syndrome is typically caused by a de novo pathogenic variant, most probands represent a simplex case (i.e., a single occurrence in a family). [11] Rarely, the family history may be consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations). [19]

Treatment

There are currently no disease specific therapies, although the use of losartan has been suggested to prevent fibrosis. [20]

History

This disorder was first reported in 1981. [21] It has many similarities to LAPS Syndrome and they both arise from the same mutations in the SMAD4 gene. It is believed that they are the same syndrome. [1]

Related Research Articles

<span class="mw-page-title-main">Kabuki syndrome</span> Medical condition

Kabuki syndrome is a rare congenital disorder of genetic origin. It affects multiple parts of the body, with varying symptoms and severity, although the most common is the characteristic facial appearance.

<span class="mw-page-title-main">Noonan syndrome</span> Genetic condition involving facial, heart, blood and skeletal features

Noonan syndrome (NS) is a genetic disorder that may present with mildly unusual facial features, short height, congenital heart disease, bleeding problems, and skeletal malformations. Facial features include widely spaced eyes, light-colored eyes, low-set ears, a short neck, and a small lower jaw. Heart problems may include pulmonary valve stenosis. The breast bone may either protrude or be sunken, while the spine may be abnormally curved. Intelligence is often normal. Complications of NS can include leukemia.

<span class="mw-page-title-main">Fraser syndrome</span> Recessive genetic disorder involving eye and genital abnormalities

Fraser syndrome is an autosomal recessive congenital disorder, identified by several developmental anomalies. Fraser syndrome is named for the geneticist George R. Fraser, who first described the syndrome in 1962.

<span class="mw-page-title-main">Cohen syndrome</span> Medical condition

Cohen syndrome is a very rare autosomal recessive genetic disorder with varied expression, characterised by obesity, intellectual disability, distinct craniofacial abnormalities and potential ocular dysfunction.

<span class="mw-page-title-main">Robinow syndrome</span> Rare genetic disorder characterized by a fetal face

Robinow syndrome is an extremely rare genetic disorder characterized by short-limbed dwarfism, abnormalities in the head, face, and external genitalia, as well as vertebral segmentation. The disorder was first described in 1969 by human geneticist Meinhard Robinow, along with physicians Frederic N. Silverman and Hugo D. Smith, in the American Journal of Diseases of Children. By 2002, over 100 cases had been documented and introduced into medical literature.

<span class="mw-page-title-main">Mothers against decapentaplegic homolog 4</span> Mammalian protein found in Homo sapiens

SMAD4, also called SMAD family member 4, Mothers against decapentaplegic homolog 4, or DPC4 is a highly conserved protein present in all metazoans. It belongs to the SMAD family of transcription factor proteins, which act as mediators of TGF-β signal transduction. The TGFβ family of cytokines regulates critical processes during the lifecycle of metazoans, with important roles during embryo development, tissue homeostasis, regeneration, and immune regulation.

<span class="mw-page-title-main">22q13 deletion syndrome</span> Rare genetic syndrome

22q13 deletion syndrome, known as Phelan–McDermid syndrome (PMS), is a genetic disorder caused by deletions or rearrangements on the q terminal end of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion may be diagnosed as 22q13 deletion syndrome. There is disagreement among researchers as to the exact definition of 22q13 deletion syndrome. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that appears to exclude terminal deletions. The requirement to include SHANK3 in the definition is supported by many but not by those who first described 22q13 deletion syndrome.

<span class="mw-page-title-main">Arterial tortuosity syndrome</span> Medical condition

Arterial tortuosity syndrome is an extremely rare congenital connective tissue condition disorder characterized by tortuosity, elongation, stenosis, or aneurysms in major and medium-size arteries including the aorta.

<span class="mw-page-title-main">Ablepharon macrostomia syndrome</span> Medical condition

Ablepharon macrostomia syndrome (AMS) is an extremely rare, autosomal dominant genetic disorder characterized by abnormal phenotypic appearances that primarily affect the head and face as well as the skull, skin, fingers and genitals. AMS generally results in abnormal ectoderm-derived structures. The most prominent abnormality is the underdevelopment (microblepharon) or absence of eyelids – signifying the ablepharon aspect of the disease – and a wide, fish-like mouth – macrostomia. Recent scholars and surgeons have called into question the naming of the condition as "Ablepharon" on account of recent investigation and histology showing consistent evidence of at least some eyelid tissue. Infants presenting with AMS may also have malformations of the abdominal wall and nipples. Children with AMS might also experience issues with learning development, language difficulties and intellectual disabilities.

<span class="mw-page-title-main">Yunis–Varon syndrome</span> Medical condition

Yunis–Varon syndrome (YVS), also called cleidocranial dysplasia with micrognathia or absent thumbs and distal aphalangia, is an extremely rare autosomal recessive multisystem congenital disorder which affects the skeletal system, ectodermal tissue, heart and respiratory system. It was first described by Emilio Yunis and Humberto Váron from the National University of Colombia.

<span class="mw-page-title-main">3C syndrome</span> Medical condition

3C syndrome is a rare condition whose symptoms include heart defects, cerebellar hypoplasia, and cranial dysmorphism. It was first described in the medical literature in 1987 by Ritscher and Schinzel, for whom the disorder is sometimes named.

<span class="mw-page-title-main">Fibrillin-1</span> Protein found in humans

Fibrillin-1 is a protein that in humans is encoded by the FBN1 gene, located on chromosome 15. It is a large, extracellular matrix glycoprotein that serves as a structural component of 10–12 nm calcium-binding microfibrils. These microfibrils provide force bearing structural support in elastic and nonelastic connective tissue throughout the body. Mutations altering the protein can result in a variety of phenotypic effects differing widely in their severity, including fetal death, developmental problems, Marfan syndrome or in some cases Weill-Marchesani syndrome.

<span class="mw-page-title-main">Keutel syndrome</span> Medical condition

Keutel syndrome (KS) is a rare autosomal recessive genetic disorder characterized by abnormal diffuse cartilage calcification, hypoplasia of the mid-face, peripheral pulmonary stenosis, hearing loss, short distal phalanges (tips) of the fingers and mild mental retardation. Individuals with KS often present with peripheral pulmonary stenosis, brachytelephalangism, sloping forehead, midface hypoplasia, and receding chin. It is associated with abnormalities in the gene coding for matrix gla protein, MGP. Being an autosomal recessive disorder, it may be inherited from two unaffected, abnormal MGP-carrying parents. Thus, people who inherit two affected MGP alleles will likely inherit KS.

<span class="mw-page-title-main">Ciliopathy</span> Genetic disease resulting in abnormal formation or function of cilia

A ciliopathy is any genetic disorder that affects the cellular cilia or the cilia anchoring structures, the basal bodies, or ciliary function. Primary cilia are important in guiding the process of development, so abnormal ciliary function while an embryo is developing can lead to a set of malformations that can occur regardless of the particular genetic problem. The similarity of the clinical features of these developmental disorders means that they form a recognizable cluster of syndromes, loosely attributed to abnormal ciliary function and hence called ciliopathies. Regardless of the actual genetic cause, it is clustering of a set of characteristic physiological features which define whether a syndrome is a ciliopathy.

<span class="mw-page-title-main">Gillespie syndrome</span> Medical condition

Gillespie syndrome, also called aniridia, cerebellar ataxia and mental deficiency, is a rare genetic disorder. The disorder is characterized by partial aniridia, ataxia, and, in most cases, intellectual disability. It is heterogeneous, inherited in either an autosomal dominant or autosomal recessive manner. Gillespie syndrome was first described by American ophthalmologist Fredrick Gillespie in 1965.

<span class="mw-page-title-main">Lujan–Fryns syndrome</span> Medical condition

Lujan–Fryns syndrome (LFS) is an X-linked genetic disorder that causes mild to moderate intellectual disability and features described as Marfanoid habitus, referring to a group of physical characteristics similar to those found in Marfan syndrome. These features include a tall, thin stature and long, slender limbs. LFS is also associated with psychopathology and behavioral abnormalities, and it exhibits a number of malformations affecting the brain and heart. The disorder is inherited in an X-linked dominant manner, and is attributed to a missense mutation in the MED12 gene. There is currently no treatment or therapy for the underlying MED12 malfunction, and the exact cause of the disorder remains unclear.

<span class="mw-page-title-main">Mental retardation and microcephaly with pontine and cerebellar hypoplasia</span> Rare X-linked dominant genetic disorder

Mental retardation and microcephaly with pontine and cerebellar hypoplasia (MICPCH) – also known as mental retardation, X-linked, syndromic, Najm type (MRXSNA); X-linked intellectual deficit, Najm type; intellectual developmental disorder, X-linked, syndromic, Najm type; X-linked intellectual disability–microcephaly–pontocerebellar hypoplasia syndrome; and by variations of these terms – is a rare X-linked dominant genetic disorder of infants characterised by intellectual disability and pontocerebellar hypoplasia. It usually affects females; many males die before birth or not long after.

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a genetic disorder caused by R179 missense mutations in the ACTA2 gene. Initially described as a case report in 1999, it was characterized in 2010 as a syndrome of congenital mydriasis, patent ductus arteriosus, and aneurysmal arterial disease—in particular aortic and thoracic aneurysms. The disorder has variable penetrance, ranging from severely symptomatic and fatal in early neonatal period to a more benign and manageable course with surgical intervention.

ZC4H2 is a protein-coding gene located on the X-chromosome. This gene encodes a protein which is a member of the so-called zinc finger domain-containing protein family. There is currently very limited understanding about the ZC4H2 gene and its protein function.

<span class="mw-page-title-main">Strømme syndrome</span> Rare genetic condition involving intestinal atresia, eye abnormalities and microcephaly

Strømme syndrome is a very rare autosomal recessive genetic condition characterised by intestinal atresia, eye abnormalities and microcephaly. The intestinal atresia is of the "apple-peel" type, in which the remaining intestine is twisted around its main artery. The front third of the eye is typically underdeveloped, and there is usually moderate developmental delay. Less common features include an atrial septal defect, increased muscle tone or skeletal abnormalities. Physical features may include short stature, large, low-set ears, a small jaw, a large mouth, epicanthic folds, or fine, sparse hair.

References

This article incorporates text from the United States National Library of Medicine  (), which is in the public domain.

  1. 1 2 Lindor NM, Gunawardena SR, Thibodeau SN. Mutations of SMAD4 account for both LAPS and Myhre syndromes. Am J Med Genet A. 2012;158a(6):1520-1.
  2. ↑ RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Myhre syndrome". www.orpha.net. Retrieved 27 December 2017.{{cite web}}: CS1 maint: numeric names: authors list (link)
  3. 1 2 Caputo, Viviana; Bocchinfuso, Gianfranco; Castori, Marco; Traversa, Alice; Pizzuti, Antonio; Stella, Lorenzo; Grammatico, Paola; Tartaglia, Marco (2014). "Novel SMAD4 mutation causing Myhre syndrome". American Journal of Medical Genetics Part A. 164 (7): 1835–1840. doi:10.1002/ajmg.a.36544. PMID   24715504.
  4. ↑ Lin, Angela E.; Brunetti-Pierri, Nicola; Lindsay, Mark E.; Schimmenti, Lisa A.; Starr, Lois J. (1993), Adam, Margaret P.; Feldman, Jerry; Mirzaa, Ghayda M.; Pagon, Roberta A. (eds.), "Myhre Syndrome", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID   28406602 , retrieved 2024-12-23
  5. ↑ Starr, Lois J.; Lindsay, Mark E.; Perry, Deborah; Gheewalla, Gregory; VanderLaan, Paul A.; Majid, Adnan; Strange, Charlie; Costea, George-Claudiu; Lungu, Adrian; Lin, Angela E. (2022). "Review of the Pathologic Characteristics in Myhre Syndrome: Gain-of-Function Pathogenic Variants in SMAD4 cause a Multisystem Fibroproliferative Response". Pediatric and Developmental Pathology. 25 (6): 611–623. doi:10.1177/10935266221079569. PMID   36120950.
  6. ↑ Starr, Lois J.; Grange, Dorothy K.; Delaney, Jeffrey W.; Yetman, Anji T.; Hammel, James M.; Sanmann, Jennifer N.; Perry, Deborah A.; Schaefer, G. Bradley; Olney, Ann Haskins (2015). "Myhre syndrome: Clinical features and restrictive cardiopulmonary complications". American Journal of Medical Genetics Part A. 167 (12): 2893–2901. doi:10.1002/ajmg.a.37273. PMID   26420300.
  7. ↑ Lindsay, Mark E.; Scimone, Eleanor R.; Lawton, Joseph; Richa, Rashmi; Yonker, Lael M.; Di, Yuanpu P.; Buch, Karen; Ouyang, Wukun; Mo, Xiulei; Lin, Angela E.; Mou, Hongmei (2024). "Gain-of-function variants in SMAD4 compromise respiratory epithelial function". The Journal of Allergy and Clinical Immunology: S0091–6749(24)00908–4. doi:10.1016/j.jaci.2024.08.024. PMID   39243984.
  8. ↑ Gallione, Carol; Aylsworth, Arthur S.; Beis, Jill; Berk, Terri; Bernhardt, Barbara; Clark, Robin D.; Clericuzio, Carol; Danesino, Cesare; Drautz, Joanne; Fahl, Jeffrey; Fan, Zheng; Faughnan, Marie E.; Ganguly, Arupa; Garvie, John; Henderson, Katharine (2010). "Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome". American Journal of Medical Genetics. Part A. 152A (2): 333–339. doi:10.1002/ajmg.a.33206. PMID   20101697.
  9. 1 2 Gheewalla, Gregory M.; Luther, Jay; Das, Saumya; Kreher, Jeffrey B.; Scimone, Eleanor R.; Wong, Ashley W.; Lindsay, Mark E.; Lin, Angela E. (2022). "An additional patient with SMAD4-Juvenile Polyposis-Hereditary hemorrhagic telangiectasia and connective tissue abnormalities: SMAD4 loss-of-function and gain-of-function pathogenic variants result in contrasting phenotypes". American Journal of Medical Genetics. Part A. 188 (10): 3084–3088. doi:10.1002/ajmg.a.62915. PMID   35869926.
  10. ↑ Heldin, Carl-Henrik; Miyazono, Kohei; ten Dijke, Peter (1997). "TGF-β signalling from cell membrane to nucleus through SMAD proteins". Nature. 390 (6659): 465–471. Bibcode:1997Natur.390..465H. doi:10.1038/37284. PMID   9393997.
  11. 1 2 3 Lin, Angela E.; Scimone, Eleanor R.; Thom, Robyn P.; Balaguru, Duraisamy; Kinane, T. Bernard; Moschovis, Peter P.; Cohen, Michael S.; Tan, Weizhen; Hague, Cole D.; Dannheim, Katelyn; Levitsky, Lynne L.; Lilly, Evelyn; DiGiacomo, Daniel V.; Masse, Kara M.; Kadzielski, Sarah M. (2024). "Emergence of the natural history of Myhre syndrome: 47 patients evaluated in the Massachusetts General Hospital Myhre Syndrome Clinic (2016–2023)". American Journal of Medical Genetics Part A. 194 (10): e63638. doi:10.1002/ajmg.a.63638. PMC   11586855 . PMID   38779990.
  12. ↑ Cappuccio, Gerarda; Brunetti-Pierri, Nicola; Clift, Paul; Learn, Christopher; Dykes, John C.; Mercer, Catherine L.; Callewaert, Bert; Meerschaut, Ilse; Spinelli, Alessandro Mauro; Bruno, Irene; Gillespie, Matthew J.; Dorfman, Aaron T.; Grimberg, Adda; Lindsay, Mark E.; Lin, Angela E. (2022). "Expanded cardiovascular phenotype of Myhre syndrome includes tetralogy of Fallot suggesting a role for in human neural crest defects". American Journal of Medical Genetics Part A. 188 (5): 1384–1395. doi:10.1002/ajmg.a.62645. PMID   35025139.
  13. ↑ Le Goff, C.; Michot, C.; Cormier-Daire, V. (2014). "Myhre syndrome". Clinical Genetics. 85 (6): 503–513. doi:10.1111/cge.12365. PMID   24580733.
  14. ↑ Alape, Daniel; Singh, Rani; Folch, Erik; Fernandez Bussy, Sebastian; Agnew, Alexis; Majid, Adnan (2020). "Life-Threatening Multilevel Airway Stenosis Due to Myhre Syndrome". American Journal of Respiratory and Critical Care Medicine. 201 (6): 731–732. doi:10.1164/rccm.201905-0922im. PMID   31539271.
  15. ↑ Yang, David Dawei; Rio, Marlene; Michot, Caroline; Boddaert, Nathalie; Yacoub, Wael; Garcelon, Nicolas; Thierry, Briac; Bonnet, Damien; Rondeau, Sophie; Herve, Dominique; Guey, Stephanie; Angoulvant, Francois; Cormier-Daire, Valerie (2022). "Natural history of Myhre syndrome". Orphanet Journal of Rare Diseases. 17 (1): 304. doi: 10.1186/s13023-022-02447-x . PMC   9338657 . PMID   35907855.
  16. ↑ Vanbelleghem, Eva; Van Damme, Tim; Beyens, Aude; Symoens, Sofie; Claes, Kathleen; De Backer, Julie; Meerschaut, Ilse; Vanommeslaeghe, Floris; Delanghe, Sigurd E.; van den Ende, Jenneke; Beyltjens, Tessi; Scimone, Eleanor R.; Lindsay, Mark E.; Schimmenti, Lisa A.; Hinze, Alicia M. (2024). "Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations". European Journal of Human Genetics: EJHG. 32 (9): 1086–1094. doi:10.1038/s41431-024-01664-1. PMC  11369149. PMID   38997468.
  17. ↑ Shi, Yigong; Massagué, Joan (2003). "Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus". Cell. 113 (6): 685–700. doi:10.1016/s0092-8674(03)00432-x. PMID   12809600.
  18. 1 2 Le Goff, Carine; Mahaut, Clémentine; Abhyankar, Avinash; Le Goff, Wilfried; Serre, Valérie; Afenjar, Alexandra; Destrée, Anne; di Rocco, Maja; Héron, Delphine; Jacquemont, Sébastien; Marlin, Sandrine; Simon, Marleen; Tolmie, John; Verloes, Alain; Casanova, Jean-Laurent; Munnich, Arnold; Cormier-Daire, Valérie (December 2011). "Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome". Nature Genetics. 44 (1): 85–88. doi:10.1038/ng.1016. PMID   22158539. S2CID   13042633 . Retrieved 11 July 2015.
  19. ↑ Meerschaut, Ilse; Beyens, Aude; Steyaert, Wouter; De Rycke, Riet; Bonte, Katrien; De Backer, Tine; Janssens, Sandra; Panzer, Joseph; Plasschaert, Frank; De Wolf, Daniël; Callewaert, Bert (2019). "Myhre syndrome: A first familial recurrence and broadening of the phenotypic spectrum". American Journal of Medical Genetics Part A. 179 (12): 2494–2499. doi:10.1002/ajmg.a.61377. PMID   31595668.
  20. ↑ Cappuccio, Gerarda; Caiazza, Martina; Roca, Alessandro; Melis, Daniela; Iuliano, Antonella; Matyas, Gabor; Rubino, Marta; Limongelli, Giuseppe; Brunetti-Pierri, Nicola (2021). "A pilot clinical trial with losartan in Myhre syndrome". American Journal of Medical Genetics Part A. 185 (3): 702–709. doi:10.1002/ajmg.a.62019. PMC   7898344 . PMID   33369056.
  21. ↑ Myhre, Selma A.; Ruvalcaba, Rogelio H. A.; Graham, C. Benjamin (1981). "A new growth deficiency syndrome". Clinical Genetics. 20 (1): 1–5. doi:10.1111/j.1399-0004.1981.tb01798.x. PMID   7296942.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.